“In particular, medtech companies should be cautious and implement stringent oversight over third-party consultants, intermediaries, agents, distributors, and others that negotiate or interact with Mexican government officials or representatives of state-owned entities, as these types of relationships have proved fertile ground for FCPA cases in recent years, as have interactions with customs officials." —Nicholas Berg, attorney, Ropes & Gray
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?